Procter & Gamble Health Ltd. (IN:PGHL)
:PGHL
Want to see IN:PGHL full AI Analyst Report?
PGHL Stock Chart & Stats
₹5751.70
-₹54.70(-1.07%)
At close: 4:00 PM EST
₹5751.70
-₹54.70(-1.07%)
Day’s Range― - ―
52-Week Range₹4,699.70 - ₹6,700.00
Previous CloseN/A
Volume2.65K
Average Volume (3M)310.00
Market Cap
₹88.67B
Enterprise Value₹86.17B
Total Cash (Recent Filing)₹2.86B
Total Debt (Recent Filing)₹95.50M
Price to Earnings (P/E)30.5
Beta0.54
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)184.83
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)15.96
Price to Sales (P/S)7.03
P/FCF Ratio51.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)219
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and very high ROE provide durable financial flexibility. This capital structure supports sustained investment in distribution, marketing, and working capital, reduces default risk in downturns, and enables consistent shareholder returns or opportunistic M&A over months to years.
Cash GenerationHigh free cash flow relative to net income indicates strong cash conversion, supporting reinvestment, dividends, and resilience to cost shocks. Reliable cash generation underpins long-term funding for brand-building and supply-chain improvements without heavy new borrowing.
Profitability & Revenue GrowthConsistent margin expansion alongside mid-single-digit revenue growth shows structural demand and pricing power in OTC healthcare. Durable profitability supports sustained operating cash flow and allows continued marketing and distribution investment to defend market share.
Bears Say
Margin PressureA falling gross margin signals input cost or mix pressure that can erode durable profitability if persistent. Without offsetting pricing or productivity gains, margin compression reduces cash available for reinvestment and weakens long-term earnings resilience.
Operational EfficiencyOperating cash flow trailing net income suggests working capital or receivables management inefficiencies. If not improved, it could constrain free cash flow in tougher cycles, limit funding for growth initiatives, and pressure liquidity despite strong accounting profits.
Modest EPS MomentumLow single-digit EPS growth points to modest earnings acceleration versus peers. Over the medium term this may limit scope for rapid shareholder return expansion absent faster revenue gains or meaningful margin improvement, constraining upside from fundamentals alone.
Procter & Gamble Health Ltd. News
PGHL FAQ
What was Procter & Gamble Health Ltd.’s price range in the past 12 months?
Procter & Gamble Health Ltd. lowest stock price was ₹4699.70 and its highest was ₹6700.00 in the past 12 months.
What is Procter & Gamble Health Ltd.’s market cap?
Procter & Gamble Health Ltd.’s market cap is ₹88.67B.
When is Procter & Gamble Health Ltd.’s upcoming earnings report date?
Procter & Gamble Health Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 97 days.
How were Procter & Gamble Health Ltd.’s earnings last quarter?
Procter & Gamble Health Ltd. released its earnings results on Apr 30, 2026. The company reported ₹46.743 earnings per share for the quarter, missing the consensus estimate of ₹4512.949 by -₹4466.206.
Is Procter & Gamble Health Ltd. overvalued?
According to Wall Street analysts Procter & Gamble Health Ltd.’s price is currently Overvalued.
Does Procter & Gamble Health Ltd. pay dividends?
Procter & Gamble Health Ltd. pays a Semiannually dividend of ₹45 which represents an annual dividend yield of 3.28%. See more information on Procter & Gamble Health Ltd. dividends here
What is Procter & Gamble Health Ltd.’s EPS estimate?
Procter & Gamble Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Procter & Gamble Health Ltd. have?
Procter & Gamble Health Ltd. has 16,599,382 shares outstanding.
What happened to Procter & Gamble Health Ltd.’s price movement after its last earnings report?
Procter & Gamble Health Ltd. reported an EPS of ₹46.743 in its last earnings report, missing expectations of ₹4512.949. Following the earnings report the stock price went up 1.331%.
Which hedge fund is a major shareholder of Procter & Gamble Health Ltd.?
Currently, no hedge funds are holding shares in IN:PGHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Procter & Gamble Health Ltd.
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands. Procter & Gamble Health Limited also exports its pharmaceutical products to Sri Lanka, Nepal, Myanmar, and Maldives. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Technical Analysis
Amrutanjan Health Care Limited
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Zydus Lifesciences Limited
―